IMS Health in the News
Pharmaceutical Commerce, May/June 2014
Kjel Johnson is included in an article that discusses how a rising course of new, expensive therapies is transforming relationships among payers and providers.
PM360, April 2014
Insights from Angeliki Cooney are included in this article about how the pharmaceutical, biotech and medical device companies provide a new opportunity and challenge for the accountable care organizations (ACOs).
Pharmaceutical Executive, March 2014
Mason Tenaglia discusses a new set of metrics to help companies maximize the effectiveness and impact of their promotional resources in the midst of mounting competitive market pressures.
PharmaPhorum, March 2014
Adam Collier examines the emerging need for Real-World Evidence data to meet the increasing scrutiny and demands of healthcare decision makers.
PM360, February 2014
Bob Harrell discusses the four key factors and requirements needed to build meaningful customer relationships.
PharmaVOICE, February 2014
Mason Tenaglia discusses the many challenges that lie ahead for the specialty drug market, including changes in the reimbursement process due to healthcare reform, financial and regulatory pressures, and the need to expand communication to all stakeholders.
Pharmaceutical Executive, October 2013
Mason Tenaglia discusses key provisions of the Affordable Care Act and its impact on the future of the pharmaceutical industry business model.
PM360, December 2013
IMS Health appears in the Special Innovation issue, where we discuss how IMS Health is answering the current needs of Pharma marketers and helping our Life Science customers keep pace with the transformation in healthcare.
PM360, December 2013
Eileen Moyer and Matt Hallett discuss the need for brand teams to have knowledge and awareness of the data they need, how it can be consumed and the functionality that is needed to implement effective marketing campaigns.
PM360, November 2013
Angeliki Cooney discusses the importance of integrated delivery networks and accountable care organizations in the prescribing process.
MM&M, October 2013
Bob Harrell discusses its cloud-based system Journeys, which shows how customers are behaving in real time, providing opportunities to create fully-automated, rules-based marketing campaigns.
PM360, October 2013
Anette Lillegard discusses a variety of challenges to health marketers in the social media space, including adverse event reporting, Facebook and YouTube, and healthcare-related mobile apps.
pharmaphorum, September 2013
Carolyn Gauntlett discusses the growing global prevalence of diabetes, but more specifically in the Middle East and North Africa (MENA) and how pharma companies in this region are addressing this epidemic.
PharmaVoice, September 2013
Knowing who’s who among customers is no longer enough to guide pharmaceutical sales and marketing decisions; it's now vital to know who is influenced by whom across professionals and organizations. John Busalacchi and Eileen Moyer discuss the importance of having an effective and efficient Master Data Management strategy, and applying best practices in data governance and stewardship.
PM360, August 2013
John Giannouris and Chris Bayles discuss a best-practice approach to acquiring data to support specialty brand decision making.
Murray Aitken, Executive Director of the IMS Institute for Healthcare Informatics, discusses key findings from the new IMS Institute report Declining Medicine Use and Costs: For Better or Worse? Listen to his commentary.
Pharma Voice, January 2013
Insights from Angeliki Cooney and Rob Hollis are included in this article on how the commercial pharma industry is actively engaged in how accountable care organizations (ACOs) deliver healthcare to Medicare patients. ACOs, which deliver integrated and coordinated care to Medicare patients, focus on evidence- and protocol-based models to drive improved treatment quality and cost savings.
Pharmaceutical Commerce, September/October 2012
Chris Leibfreid and Suzann Sullivan discuss how co-pay cards and other discounting programs can optimize an organization’s rebate spend and improve contract pull-through at the local level.
PM360, September 2012
Jody Fisher discusses how metrics from anonymous patient level data can be developed to provide a rapid assessment that examines regional areas where uptake of market share is not meeting expectations for the GERD market.
PharmaVOICE, September 2012
Big data, the avalanche of healthcare information on its way, represents a significant opportunity for pharmaceutical manufacturers. John Busalacchi and Eileen Moyer discuss how new sources of information, including electronic medical records, social media, real-world evidence, personalized medicine, and track-and trace systems, promise companies better clinical and commercial insights for competitive advantage.
pharmaphorum, September 2012
IMS believes that the threshold of $1bn for a blockbuster drug is completely outdated and a new, more realistic threshold would drastically cut the number of blockbuster products and change what it means to be successful in the future.
PM360, June 2012
Aimee Ruscio and Catherine Balderston McGuiness discuss determining the market size of complex markets using anonymized, longitudinal, patient-level data.
Bloomberg, June 12, 2102
The Japanese government and the pharmaceutical industry have worked to speed up drug approvals in Japan where a complex regulatory environment had delayed treatments for an aging population for years. IMS’s Alan Johnson discusses industry growth and the complexity of pricing drugs in Japan.
PM360, May 2012
Today, manufacturers can leverage anonymized, patient-level data (APLD) to further refine their prescriber evaluation methods rather than relying on looking at historical prescribing volumes. Alex Baranov and Heather von Allmen define methods for identifying physicians who fit a target profile or who treat the patients of most value to a brand team.
The Pink Sheet, May 21, 2012
Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs. IMS’s Suzanne Sullivan offers commentary about Lipitor and similar drugs that also faced loss of exclusivity in recent years.
Pharmaceutical Executive, May 2012
New sources of clinical and commercial information have proliferated the pharmaceutical industry, requiring companies to become technology agnostic. Don Ragas discusses the benefits and challenges of “big data” in this contributed article.
Pharmaceutical Commerce, May/June 2012
While cancer remains the second leading cause of death in the U.S., the survival rate has been rising. Jane Quigley offers insights into the complexities and dynamics of the oncology market.
PharmaVOICE, May 2012
Pharmaceutical marketers are continuing to look for ways to drive cost savings and return on investment for their marketing programs. In this PharmaVOICE roundtable discussion, Gregory Ford discusses regional marketing segmentation and strategies.
Pharmaphorum, May 2, 2012
The ability of mobile devices to connect the customer, field sales and central management will significantly shape the future of sales force effectiveness (SFE), in the pharmaceuticals market, in the coming years. This article and video uncovers the changing SFE landscape in pharma.
PM360, April 2012
The overactive bladder (OAB) market is one familiar to most because of catchy jingles in direct-to-consumer advertising campaigns. Melissa Leonhauser analyzes the current leaders and Pfizer’s and AstraZeneca’s strategies to ensure successful futures in the market.
World Health Care Congress, April 16, 2102
This video features discussion by Murray Aitken about the importance of understanding the spending and utilization patterns for healthcare services among privately insured individuals under age 65 .
PM360, March 2012
Prescriptions dispensed in hospitals can have an extended impact on a brand’s success as many patients receive prescriptions to fill afterwards at a retail pharmacy. Gregory Ford explains how the impact of hospital prescribing shouldn’t be underestimated and how using anonymous patient-level data allows brand teams to identify strategies to improves their success.
PM360, February 2012
In this installment of PM360’s MarketWatch series, Melissa Leonhauser evaluates the factors affecting success of brands in the hypertension market and demonstrates how excellent managed care coverage has boosted prescriptions for the leading angiotensin receptor blockers (ARBs).
CBS Evening News, February 14, 2012
Thousands of children count on methotrexate to fight the childhood cancer, acute lymphoblastic leukemia, but supplies are running dangerously low. Details from the IMS Institute’s drug shortages report is featured in this news story.
The New York Times, February 28, 2012
One percent of patients account for more than 25 percent of healthcare spending among the privately insured, with medical bills nearing $100,000. The IMS Institute’s newest report, Spending Among Privately Insured Individuals Under Age 65, and commentary by Dan Malloy is featured.
Pharmaceutical Executive Europe, February 22, 2012
Major pharmaceutical companies are scrambling to meet the challenge of supplementing the clinical trial with “real world” evidence. IMS’s Jon Resnick discusses how to best advance the use of real-world evidence and IMS’s European collaboration with AstraZeneca.
PharmaVoice, February 2012
Biosimilars could amount to a multi-billion dollar market in the US, but uncertainty still exists as manufacturers wait for guidance from the FDA. Alan Sheppard comments about opportunities and challenges facing manufactures.
USAToday, November 29, 2011
Pfizer has devised discounts and incentives for patients, insurers and companies that process Lipitor prescriptions that will, at least for the next six months, give patients access to the brand name drug for about the same cost as generics. Michael Kleinrock comments on Pfizer’s strategy and the benefits Lipitor brings to patients.
National Public Radio: The TakeAway, November 30, 2011
Millions of Americans taking Lipitor will be given a choice to stay on the medication or switch to the generic, as the 20 year patent for the blockbuster prescription drug expires. And Pfizer, the drug’s maker, is moving quickly to keep patients on the name brand. The IMS Institute’s Michael Kleinrock discusses Pfizer’s strategy and the benefits that Lipitor continues to deliver to patients.
GPhA Report, Sep 26, 2011
A study conducted by the IMS Institute for Healthcare Informatics for the Generics Pharmaceutical Association (GPhA) finds that generic versions of brand name drugs helped save the American healthcare system more than $931 Bn over the past decade.
PM360, July 2011
New public-payer schemes are driving providers away from fee-for-service and toward outcome-based payments. With the rules of the road changing, companies must refine their commercial strategies by using real-world evidence that demonstrates product value and improves quality and patient outcomes.
The Hill, July 15, 2011
The Hill reports on the IMS Institute report, Medicare Part D at Age Five: What Has Happened to Seniors’ Prescription Drug Prices?
Reuters, July 15, 2011
The trend toward less costly generic drugs are identified as a key factor that could temper growing costs of the Medicare Part prescription program for seniors and disabled patients.
Pharmaceutical Market Europe, May 2011
Turkey has always been a bridge between Europe and Asia with untapped promise in a variety of industries. We explore the unique opportunities this market offers and how pharmaceutical manufacturers can tap into its potential.
Bloomberg, May 18, 2011
Bloomberg reports on the IMS Institute for Healthcare Informatics study, The Global Use of Medicines: Outlook through 2015, including extensive commentary on key drivers of future healthcare spending.
PharmExecBlog, May 18, 2011
Murray Aitken, executive director for the IMS Institute for Healthcare Informatics discusses estimated growth and the regulatory pathway for biosimilars and the in the United States.
Reuters, May 18, 2011
Murray Aitken, executive director, IMS Institute for Healthcare Informatics, discusses key market dynamics expected to drive healthcare spending through 2015, pointing to generics as one of those growth drivers.
In the latest issue of ACCESSPOINT, IMS HEOR experts provide insights to the latest U.S. healthcare reforms, market access changes in Germany, HTA convergence, and other pivotal dynamics driving change, challenge and potential for health and economics outcomes research.
The Chicago Tribune, May 4, 2011
More than $100 billion in annual brand-name drug sales will be at risk for generic competition from 2011 to 2015. That's about one-third of the annual spending on all prescription drugs in the U.S., according to IMS data.
The TB Alliance and the Bill and Melinda Gates Foundation partnered with IMS on this published study, which concludes that the expansion of diagnosis and treatment in the public sector could have a greater impact in strengthening TB treatment outcomes.
Next Generation Pharma, April 2011
IMS Consulting Group's Chris Nickum details the path to more effective pharma commercial models and greater efficiency in promotional spend strategies.
Associated Press, April 19, 2011
The article features insights from the IMS Institute for Healthcare Informatics report, Use of Medicines in the United States: Review of 2010.
The Wall Street Journal Health Blog, April 19, 2011
Key market drivers in 2010, including generic growth and the dynamics around spending and the most widely prescribed products, are outlined, based on the IMS Institute for Healthcare Informatics study, The Use of Medicines in the United States: Review of 2010.
Reuters, April 19, 2011
The IMS Institute for Healthcare Informatics study, Use of Medicines in the United States: Review of 2010, is featured. In the story, Reuters cites the greater use of cheaper generic medicines, less spending on new therapies and fewer patients visiting doctors to begin treatments for chronic illnesses as key factors that contributed to the market's slowing growth.